



REVIEW

# Protecting the heart in cancer therapy [version 1; referees: 2 approved]

J. Emanuel Finet<sup>1</sup>, W. H. Wilson Tang <sup>1,2</sup>

<sup>1</sup>Section of Heart Failure and Transplantation Medicine, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, and Sydell and Arnold Miller Family Heart and Vascular Institute, Cleveland Clinic, Cleveland, USA

<sup>2</sup>Cleveland Clinic Lerner College of Medicine at Case Western Reserve University; Center for Clinical Genomics; Cleveland Clinic, Cleveland, USA

**v1** **First published:** 28 Sep 2018, 7(F1000 Faculty Rev):1566 (doi: 10.12688/f1000research.15190.1)  
**Latest published:** 28 Sep 2018, 7(F1000 Faculty Rev):1566 (doi: 10.12688/f1000research.15190.1)

**Abstract**



Recent advances in cancer prevention and management have led to an exponential increase of cancer survivors worldwide. Regrettably, cardiovascular disease has risen in the aftermath as one of the most devastating consequences of cancer therapies. In this work, we define cancer therapeutics-induced cardiotoxicity as the direct or indirect cardiovascular injury or injurious effect caused by cancer therapies. We describe four progressive stages of this condition and four corresponding levels of prevention, each having a specific goal, focus, and means of action. We subsequently unfold this didactic framework, surveying mechanisms of cardiotoxicity, risk factors, cardioprotectants, biomarkers, and diagnostic imaging modalities. Finally, we outline the most current evidence-based recommendations in this area according to multidisciplinary expert consensus guidelines.

**Keywords**

Cardiovascular disease, cancer, heart, cardioprotection, cardiotoxicity, prevention, biomarkers

**Open Peer Review**

**Referee Status:** 

	Invited Referees	
	1	2
<b>version 1</b> published 28 Sep 2018		

F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty. In order to make these reviews as comprehensive and accessible as possible, peer review takes place before publication; the referees are listed below, but their reports are not formally published.

- <sup>1</sup> **Edimar A Bocchi**, Heart Institute (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil  
**Monica S Ávila**, Heart Institute (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil
- <sup>2</sup> **Ana Barac**, Medstar Washington Hospital Center, Medstar Heart and Vascular Institute, USA

**Discuss this article**

Comments (0)

**Corresponding authors:** J. Emanuel Finet ([finetj@ccf.org](mailto:finetj@ccf.org)), W. H. Wilson Tang ([tangw@ccf.org](mailto:tangw@ccf.org))

**Author roles:** **Finet JE:** Conceptualization, Data Curation, Writing – Original Draft Preparation; **Tang WHW:** Conceptualization, Funding Acquisition, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**Grant information:** W. H. Wilson Tang is supported by grants from the National Institutes of Health (R01HL103866, P20HL113452, R01DK106000, and R01HL126827).

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Copyright:** © 2018 Finet JE and Tang WHW. This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Finet JE and Tang WHW. **Protecting the heart in cancer therapy [version 1; referees: 2 approved]** *F1000Research* 2018, 7(F1000 Faculty Rev):1566 (doi: [10.12688/f1000research.15190.1](https://doi.org/10.12688/f1000research.15190.1))

**First published:** 28 Sep 2018, 7(F1000 Faculty Rev):1566 (doi: [10.12688/f1000research.15190.1](https://doi.org/10.12688/f1000research.15190.1))

## Introduction

Recent advances in cancer prevention and management have led to an exponential increase of cancer survivors worldwide<sup>1</sup>. Regrettably, cardiovascular disease (CVD) has risen in the aftermath as one of the most devastating consequences of cancer therapies<sup>2,3</sup>, being most prevalent in adult survivors of breast cancer and hematological malignancies<sup>1,4,5</sup>.

In this work, we define cancer therapeutics-induced cardiotoxicity (CTIC) as the direct or indirect cardiovascular injury or injurious effect caused by cancer therapies, such as mediastinal radiotherapy<sup>6</sup> and/or some chemotherapeutic agents<sup>7</sup>. These incipient toxic changes (e.g. cardiomyocyte apoptosis, cardiac ion-channel alteration, endothelial damage, etc.) can further develop into complex cardiovascular conditions, such as heart failure (HF), valvular heart disease, coronary artery disease (CAD), pericardial disease, systemic and pulmonary hypertension, arrhythmias, and thromboembolic disease, among others<sup>8,9</sup>. Concomitant pre-existent cardiovascular risk factors have been shown to foment this pathogenesis<sup>10</sup>.

## Pathogenesis of cancer therapeutics-induced cardiotoxicity

### Cardiotoxic chemotherapy

Doxorubicin (and other agents in the anthracycline family) is the archetype chemotherapeutic leading to CTIC, historically called anthracycline-induced cardiotoxicity or anthracycline-induced cardiomyopathy (AIC)<sup>11</sup>. The hallmark of this condition is a HF syndrome arising from dilated cardiomyopathy (DCM)<sup>11</sup>; supraventricular and ventricular arrhythmias have also been described during anthracycline administration but seldom require intervention<sup>12</sup>. Its prevalence has not been thoroughly studied owing to lack of a uniform definition, inconsistent diagnostic criteria, and underreporting; in modern times, it is thought to affect 17–23% of survivors of pediatric hematological malignancies<sup>13–15</sup> and accounts for 2.6% of all patients with non-ischemic cardiomyopathy undergoing cardiac transplantation<sup>16</sup>.

In addition to anthracyclines, an increasing number of chemotherapeutic agents have been labeled as “cardiotoxic”, with particular mechanisms of action that lead to distinctive cardiovascular effects, and in turn various degrees of frequency and severity (see [Table 1](#) for a list of the most important cardiotoxic chemotherapeutic agents currently available in the US)<sup>7,8,17</sup>. Because historical cardiotoxicity was mediated by non-specific agents such as anthracycline and alkylating agents, it was believed that the novel “targeted therapeutics” (e.g. monoclonal antibodies, tyrosine kinase inhibitors, etc.) would provide fewer off-target adverse effects. However, an increasingly systematic evaluation and reporting of cardiovascular safety, along with a concomitant explosion of basic<sup>18</sup>, translational<sup>19</sup>, and clinical research in the area of CTIC<sup>20</sup>, have progressively revealed that a large number of these targeted agents are mechanistically determined to cause cardiotoxicity<sup>21</sup>. Based on the weight of the evidence, the US Food and Drug Administration has recently issued several cardiovascular box warnings for some of these agents, such as myocardial toxicity for anthracyclines, cardiomyopathy for ERBB2 inhibitors, QT

prolongation and sudden cardiac death for certain tyrosine kinase inhibitors, and immune-mediated adverse reactions (i.e. myocarditis) for CTLA-4 inhibitors, among others (see [Table 1](#))<sup>17</sup>.

### Cardiotoxic radiotherapy

The significant delay between exposure to mediastinal radiotherapy and manifestation of heart disease, reporting bias, and the frequent concomitant use of cardiotoxic chemotherapy precludes an accurate determination of the incidence of radiation-induced cardiotoxicity<sup>8</sup>. Having said that, it is believed that cancer survivors who have undergone chest radiotherapy have a 23% increase in absolute risk of cardiovascular morbidity and mortality after 20 years<sup>22</sup>. When considering the risk of radiotherapy-induced cardiomyopathy, for example, Hodgkin lymphoma survivors who received mediastinal radiotherapy have a fivefold increase after 30 years<sup>23</sup>, whereas the greatest risk for breast cancer survivors belongs to those who received left-sided chest radiation and concomitant anthracycline chemotherapy<sup>24</sup>. This laterality risk factor is likely related to the higher incidence of severe CAD in the mid and distal left anterior descending and distal diagonal arteries that is also present in this population, which could contribute to left ventricular (LV) dysfunction<sup>25</sup>.

Myocardial injury induced by radiotherapy has the hallmark of increased interstitial myocardial fibrosis<sup>6</sup>, which in turn leads to diastolic LV dysfunction<sup>26</sup> and subtle contractile impairment<sup>27</sup>. These pathological changes may also account for the higher incidence of conduction abnormalities, cardiovascular autonomic dysfunction, impaired exercise performance, and overall mortality<sup>28</sup>. Additionally, cardiac radiation is associated with complex stenotic and regurgitant valvular lesions<sup>29</sup>, pericardial disease<sup>6</sup>, and carotid artery disease<sup>30</sup>, among other conditions.

### Stages of cancer therapeutics-induced cardiotoxicity

Patterned after an established classification of disease progression<sup>31</sup>, we have divided CTIC into four distinct stages, i.e. A, B, C, and D (see [Figure 1](#)). Stage A CTIC refers to cancer patients with cardiovascular health. Stage B CTIC designates cancer patients with high risk of developing CTIC. Risk factors for CTIC can be broadly divided into those pertaining to the patient and those pertaining to the cancer therapies implemented (see [Table 2](#))<sup>5,30,32,33</sup>. Stage C CTIC denotes “incipient” cardiotoxicity; this is the early stages of the cardiotoxic process before it becomes clinically apparent. This stage is characterized by the appearance of abnormal biomarkers that precede the clearly defined diseased entities (e.g. QTc prolongation precedes Torsade de Pointes and sudden cardiac death, and sarcomeric protein or natriuretic peptide serum elevations precede LV dysfunction and overt heart failure, etc.). Finally, stage D CTIC refers to established cardiotoxicity, which is manifested by cardiovascular syndromes in early or late stages, that requires standard diagnostic modalities and medical and surgical therapies derived from expert consensus guidelines<sup>8,31,34–36</sup>.

### Levels of prevention

Preventive strategies for CTIC can also be divided into four standard levels, i.e. primordial, primary, secondary, and tertiary,

**Table 1. Chemotherapy agents associated with cancer therapeutics-induced cardiotoxicity.** Text in bold represents US Food and Drug Administration box warnings. 5-FU, 5-fluorouracil; ALK, anaplastic lymphoma kinase; CSF-1R, colony-stimulating factor 1 receptor; ECG, electrocardiogram; EGFR, epidermal growth factor receptor; FKBP, FK506-binding protein; FGFR, fibroblast growth factor receptor; FLT3, FMS-like tyrosine kinase 3; GST, gastrointestinal stromal tumor; GVHD, graft-versus-host disease; LT3, Lymphotoxin 3; HDAC, histone deacetylase; HGFR, hepatocyte growth factor receptor; HIF-1, hypoxia-inducible factor-1; Ig, immunoglobulin; IGF-1R, insulin-like growth factor 1-receptor; IL, interleukin; LAK, lymphokine-activated killer; mTOR, mammalian target of rapamycin; NK, natural killer; PD-1, programmed death 1; PDGFR, platelet-derived growth factor receptor; PD-L1, programmed death ligand 1; PNET, primitive neuroectodermal tumor; SCD, sudden cardiac death; TdP, Torsades de Pointes; TL, tumor-infiltrating lymphocyte; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.

Family	Agent	Chemotherapy agents associated with cancer therapeutics-induced cardiotoxicity Approved uses	Mechanism of action	Cardiovascular toxicities
Anthracyclines	Doxorubicin	Breast cancer, non-Hodgkin lymphoma, Burkitt lymphoma, mantle cell lymphoma, Hodgkin lymphoma, Waldenstrom macroglobulinemia, acute lymphocytic leukemia, small cell lung cancer, multiple myeloma, gastric cancer, bladder cancer, Wilms' tumor, bone sarcoma, soft tissue sarcoma, thymoma, neuroblastoma, hepatoblastoma, endometrial cancer	Anthracyclines bind directly to DNA (intercalation) and also inhibit DNA repair (via topoisomerase II inhibition), resulting in blockade of DNA and RNA synthesis and fragmentation of DNA. Doxorubicin is also a p53 inhibitor and powerful iron chelator; the iron-doxorubicin complex binds to DNA and cell membranes, producing free radicals that cleave the DNA and cell membranes.	Acute myocarditis, cardiomyopathy, heart failure, bradyarrhythmias and tachyarrhythmias, non-specific ST or T wave changes. <b>BOX WARNING: MYOCARDIAL TOXICITY</b>
	Daunorubicin	Acute myelocytic leukemia, acute lymphocytic leukemia, Kaposi sarcoma, non-Hodgkin lymphoma		
	Idarubicin	Acute promyelocytic leukemia, acute myelocytic leukemia		
	Epirubicin	Breast cancer, soft tissue sarcoma, bone sarcoma, gastric cancer, esophageal cancer		
	Mitoxantrone	Non-Hodgkin lymphoma, Hodgkin lymphoma, prostate cancer, breast cancer, acute promyelocytic leukemia, acute myelocytic leukemia		
Alkylating agents	Cyclophosphamide	Breast cancer, non-Hodgkin lymphoma, mantle cell lymphoma, follicular lymphoma, Burkitt lymphoma, Hodgkin lymphoma, Waldenstrom macroglobulinemia, acute lymphocytic leukemia, small cell lung cancer, lymphoma, AL amyloidosis, multiple myeloma, gastric cancer, esophageal cancer, soft tissue sarcoma, Wilms' tumor, gestational trophoblastic tumor, neuroblastoma, bone sarcoma, brain tumor, ovarian cancer, thymoma	Alkylating agents prevent cell division by cross-linking DNA strands and binding with nucleic acids and other intracellular structures, inhibiting protein synthesis and DNA synthesis, resulting in cell death.	Atrial tachyarrhythmias or bradyarrhythmias, capillary leak syndrome, cardiac arrest, cardiomyopathy, heart failure, cardiogenic shock, hemopericardium, hemorrhagic myocarditis.
	Ifosfamide	Hodgkin lymphoma, non-Hodgkin lymphoma, Burkitt lymphoma, neuroblastoma, small cell lung cancer, penile cancer, testicular cancer, hepatoblastoma, bone sarcoma, soft tissue sarcoma		
	Mitomycin	Gastric cancer, anal cancer, pancreatic cancer, lung cancer, mesothelioma, bladder cancer, breast cancer		
	Bleomycin	Hodgkin lymphoma, testicular cancer, ovarian cancer		
	Cisplatin	Bladder cancer, ovarian cancer, testicular cancer, breast cancer, cervical cancer, endometrial cancer, esophageal cancer, gastric cancer, head and neck cancer, Hodgkin lymphoma, mesothelioma, non-Hodgkin lymphoma, non-small cell lung cancer, osteosarcoma, penile cancer, small cell lung cancer		
	Trabectedin	Soft tissue sarcoma, ovarian cancer		

Chemotherapy agents associated with cancer therapeutics-induced cardiotoxicity				
Family	Agent	Approved uses		
		Mechanism of action		
		Cardiovascular toxicities		
Antimetabolites	5-FU	Breast cancer, anal cancer, gastric cancer, esophageal cancer, colorectal cancer, cervical cancer, bladder cancer, head and neck cancer, pancreatic cancer	Antimetabolites inhibit DNA polymerase, interfering with DNA and, to a lesser degree, RNA synthesis. Some agents also inhibit ribonucleotide reductase, DNA primase, and DNA ligase I.	Angina pectoris, vasospasm, myocardial infarction, non-specific ECG changes, atrial and ventricular bradyarrhythmias and tachyarrhythmias, cardiomyopathy, heart failure, pericardial effusion, cerebrovascular accident, local thrombophlebitis, pericarditis
	Capecitabine	Colorectal cancer, breast cancer, biliary cancer, esophageal cancer, pancreatic cancer, gastric cancer		
	Fludarabine	Chronic lymphocytic leukemia, acute myeloid leukemia, hematopoietic stem cell transplant, non-Hodgkin lymphoma, Waldenstrom macroglobulinemia		
	Cytarabine	Acute myelocytic leukemia, acute promyelocytic leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, primary central nervous system lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, meningial leukemia		
	Trastuzumab	Breast cancer and gastric cancer (ERBB2+)		
Anti-ERBB monoclonal antibodies	Pertuzumab		Binds to ERBB1 (EGFR) or ERBB2 (HER-2), mediating antibody-dependent cellular cytotoxicity of cells that overexpress EGFR or HER-2 proteins.	Cardiomyopathy, heart failure, peripheral edema, hypertension, arrhythmias. <b>BOX WARNING: CARDIOMYOPATHY</b> Arrhythmias, venous and arterial thromboembolism, ischemia. <b>BOX WARNING: CARDIOPULMONARY ARREST</b>
	Necitumumab	Non-small cell lung cancer (ERBB1+)		
Anti-VEGF monoclonal antibodies	Bevacizumab	Non-small cell lung cancer, cervical cancer, ovarian cancer, breast cancer, endometrial cancer, renal cell cancer, glioblastoma, soft tissue sarcoma, colorectal cancer	Binds to and neutralizes VEGF-A, preventing its association with the endothelial receptors VEGFR1 and VEGFR2, inhibiting angiogenesis and thus retarding the growth of all tissues (including metastatic tissue). Inhibits VEGFR1 and VEGFR2	Hypertension, cardiomyopathy, heart failure, peripheral edema, hypotension, venous and arterial thromboembolism, syncope, pulmonary embolism
	Aflibercept	Colorectal cancer		
	Ramucirumab	Colorectal cancer, gastric cancer, non-small cell lung cancer		
	Ipilimumab	Melanoma, small cell lung cancer		
Immune checkpoint inhibitors (monoclonal antibodies)	Nivolumab	Head and neck cancer, Hodgkin lymphoma, melanoma, non-small cell lung cancer, renal cell cancer, urothelial carcinoma, small cell lung cancer	Human IgG1 that blocks CTLA-4, which is a downregulator of T-cell activation pathways, enhancing their activation and proliferation Human IgG4 that inhibits PD-1, enhancing T-cell activation and proliferation. It potentiates the effects of CTLA-4 inhibitors Human IgG1 that inhibits PD-L1 and CD80, enhancing T-cell activation and proliferation. It potentiates the effects of CTLA-4 inhibitors	Acute myocarditis, cardiogenic shock. <b>BOX WARNING: IMMUNE-MEDIATED ADVERSE REACTIONS (including autoimmune myocarditis)</b> Peripheral edema, acute myocarditis, cardiogenic shock, pulmonary embolism Peripheral edema, venous thromboembolism Peripheral edema, hypertension Peripheral edema, myocarditis
	Pembrolizumab			
	Atezolizumab	Non-small cell lung cancer, urothelial carcinoma		
	Avelumab	Merkel cell carcinoma, urothelial carcinoma		
	Durvalumab	Urothelial carcinoma		

Chemotherapy agents associated with cancer therapeutics-induced cardiotoxicity		
Family	Agent	Approved uses
Multi-targeted (VEGFR) tyrosine kinase inhibitors	Sunitinib	Renal cell cancer, soft tissue sarcoma, GIST
	Pazopanib	Renal cell cancer, soft tissue sarcoma, thyroid cancer
	Sorafenib	Renal cell cancer, hepatocellular cancer, soft tissue sarcoma, GIST, thyroid cancer
	Axitinib	Renal cell cancer, thyroid cancer
	Lenvatinib	Renal cell cancer, thyroid cancer
	Regorafenib	Colorectal cancer, GIST, hepatocellular carcinoma
	Vandetanib	Thyroid cancer (medullary)
	Imatinib	Acute lymphocytic leukemia, acute myelocytic leukemia, GIST
	Dasatinib	Acute lymphocytic leukemia, chronic myelocytic leukemia, GIST
	Nilotinib	Chronic myelocytic leukemia, GIST
Multi-targeted (BCR-ABL) tyrosine kinase inhibitors	Bosutinib	Chronic myelocytic leukemia
	Ponatinib	Acute lymphocytic leukemia, chronic myelocytic leukemia
Multi-targeted (ALK) tyrosine kinase inhibitors	Brigatinib	Non-small cell lung cancer (EML4-ALK)
	Crizotinib	
	Ceritinib	
	Cobimetinib	
Multi-targeted (MEK) tyrosine kinase inhibitors	Trametinib	Melanoma and non-small cell lung cancer (BRAF V600E and V600K mutations)
	Vemurafenib	
	Lapatinib	
Multi-targeted (ERBB) tyrosine kinase inhibitors	Osimertinib	Breast cancer (ERBB2+)
	Carfilzomib	Multiple myeloma
Proteasome inhibitors	Bortezomib	AL amyloidosis, follicular lymphoma, mantle cell lymphoma, Waldenström macroglobulinemia, multiple myeloma

Family	Mechanism of action	Cardiovascular toxicities
Multi-targeted (VEGFR) tyrosine kinase inhibitors	Inhibits multiple receptor tyrosine kinases (VEGFR1, VEGFR2, and VEGFR3 mainly; also inhibits PDGFR $\alpha/\beta$ ; L13; FLT3; CSF-1R; RET; FGFR-1/3; cKIT; IL-2R; Lck; c-Fms; RET/PTC; CRAF; BRAF), preventing tumor growth and angiogenesis.	Hypertension, QTc prolongation, bradycardia, peripheral edema, cardiomyopathy, heart failure, chest pain, venous and arterial thromboembolism, ischemia, myocardial infarction, arrhythmias. <b>BOX WARNING: QTc PROLONGATION, TdP, AND SCD (vandetanib)</b>
	Inhibits multiple receptor tyrosine kinases (Bcr-Abl mainly; also VEGFRs, PDGFR $\beta$ ; SRC; LCK; YES; FYN; cKIT; EPHA2, among others), inducing apoptosis.	Edema (anasarca, ascites, pericardial and pleural effusion, peripheral edema, pulmonary edema, and superficial edema), hypertension, hypotension, chest pain, cardiomyopathy, heart failure, QTc prolongation, tachyarrhythmias and bradyarrhythmias, pulmonary hypertension, myocardial ischemia and infarction. <b>BOX WARNING: QTc PROLONGATION, TdP, AND SCD (nilotinib). BOX WARNING: HEART FAILURE; ARTERIAL AND VENOUS THROMBOEMBOLISM (ponatinib)</b>
	Inhibits multiple receptor tyrosine kinases (ALK, HGFR, c-MET, ROS1, IGF-1R, FLT-3, EGFR, etc.), blocking cell proliferation.	Sinus bradycardia, hypertension, QTc prolongation, edema, pulmonary embolism, syncope
	MEK1 and MEK2 inhibitors (BRAF pathway), causing decreased proliferation, cell cycle arrest and apoptosis. Some also inhibit RAS, RAF, and ERK.	Cardiomyopathy, hypertension
	Inhibits EGFR (ERBB1) and HER2 (ERBB2), regulating cellular proliferation and survival	Peripheral edema, hypotension, atrial fibrillation, QTc prolongation, retinal vein occlusion, vasculitis
	Inhibits EGFR (ERBB1) and L858R mutations), regulating cellular proliferation and survival	Peripheral edema, cardiomyopathy, heart failure, hypertension, arrhythmias
	Inhibits the 20S proteasome, leading to cell cycle arrest and apoptosis	Cardiomyopathy, QTc prolongation, venous thromboembolism, stroke
	Inhibits the 26S proteasome, leading to cell-cycle arrest, and apoptosis	Hypotension, acute pulmonary edema, cardiomyopathy, heart failure, cardiogenic shock, bradyarrhythmias and tachyarrhythmias, angina pectoris, cerebrovascular accident, venous thromboembolism, hemorrhagic stroke, myocardial infarction, pericardial effusion, pericarditis, peripheral edema, pulmonary embolism.

Chemotherapy agents associated with cancer therapeutics-induced cardiotoxicity				
Family	Agent	Approved uses	Mechanism of action	Cardiovascular toxicities
Antimicrotubule agents	Vinblastine	Hodgkin lymphoma, testicular cancer, bladder cancer, melanoma, non-small cell lung cancer, soft tissue sarcoma	Binds to tubulin and inhibits microtubulin formation; it is specific of M and S phases.	Angina, hypotension, myocardial ischemia and infarction, Raynaud's phenomenon, limb ischemia
	Paclitaxel	Breast cancer, bladder cancer, cervical cancer, endometrial cancer, esophageal cancer, gastric cancer, head and neck cancer, non-small cell lung cancer, small cell lung cancer, testicular cancer, soft tissue sarcoma, thymoma/thymic carcinoma, penile cancer, ovarian cancer	Inhibits microtubule disassembly, interfering with the late G2 mitotic phase, and inhibits cell replication. In addition, it can distort mitotic spindles, resulting in the breakage of chromosomes.	Edema, hypotension, arrhythmias, hypertension, syncope, cardiomyopathy, heart failure, venous thrombosis
	Docetaxel	Breast cancer, bladder cancer, bone sarcoma, esophageal cancer, gastric cancer, head and neck cancer, non-small cell lung cancer, small cell lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, soft tissue sarcoma, uterine sarcoma	Inhibits microtubule disassembly, interfering with the M mitotic phase, and inhibits cell replication	Hypotension, cardiomyopathy, heart failure. <b>BOX WARNING: FLUID RETENTION (including pulmonary edema)</b>
	Eribulin	Breast cancer, liposarcoma	Synthetic analogue of halichondrin B that inhibits polymerization of tubulin.	Peripheral edema, hypotension, QTc prolongation
	Ixabepilone	Breast cancer	Epothilone B analog, inhibits tubulin (G2/M phase inhibitor)	Peripheral edema, angina pectoris
Immunomodulators	IL-2	Melanoma, neuroblastoma, renal cell cancer	Promotes proliferation, differentiation, and recruitment of T and B cells, NK cells, thymocytes, LAK cells, and TILs, causing subsequent interactions between the immune system and malignant cells.	Capillary leak syndrome, acute myocarditis, hypotension, peripheral edema, cardiomyopathy, heart failure, ventricular tachyarrhythmias, cardiac arrest, myocardial infarction. <b>BOX WARNING: CARDIOPULMONARY DISEASE, CAPILLARY LEAK SYNDROME (including supraventricular and ventricular arrhythmias and myocardial infarction)</b>
	Interferon	Melanoma, renal cell cancer	Inhibits cellular growth, alters cellular differentiation and cell surface antigen expression, interferes with oncogene expression, increases phagocytic activity of macrophages, and augments cytotoxicity of lymphocytes	Chest pain, myocardial ischemia and infarction, atrial and ventricular tachyarrhythmias, edema, hypertension, cardiomyopathy, heart failure. <b>BOX WARNING: ISCHEMIC DISORDERS (including stroke and myocardial infarction)</b>
	Thalidomide	AL amyloidosis, Waldenstrom macroglobulinemia, multiple myeloma	Increases NK cell number and levels of IL-2 and interferon gamma. Also inhibits angiogenesis, increases cell-mediated cytotoxic effects, and alters the expression of cellular adhesion molecules.	Edema, deep vein thrombosis, hypotension, hypertension, chest pain, atrial tachyarrhythmias, myocardial infarction, pulmonary embolism, syncope, stroke, angina pectoris, cardiomyopathy, heart failure, cardiac arrest, cardiogenic shock, increased cardiac enzymes. <b>BOX WARNING: ARTERIAL AND VENOUS THROMBOEMBOLISM</b>
	Lenalidomide	Mantle cell lymphoma, multiple myeloma, chronic lymphocytic leukemia, myelodysplastic syndrome, AL amyloidosis, renal cell cancer, non-Hodgkin lymphoma	Inhibits secretion of proinflammatory cytokines; enhances cell-mediated immunity by stimulating proliferation of anti-CD3 stimulated T cells (resulting in increased IL-2 and interferon gamma secretion); inhibits trophic signals to angiogenic factors in cells.	

Chemotherapy agents associated with cancer therapeutics-induced cardiotoxicity				
Family	Agent	Approved uses	Mechanism of action	Cardiovascular toxicities
mTOR inhibitors	Sirolimus	<i>GVHD, renal angiomyolipoma</i>	Reduces protein synthesis and cell proliferation by binding to FKBP-12 and subsequently inhibiting mTOR activation, halting the cell cycle at the G1 phase. Also reduces angiogenesis by inhibiting VEGF and HIF-1 expression. Temsirolimus is the prodrug of sirolimus, the active metabolite. Everolimus is a sirolimus derivative.	Peripheral edema, hypertension, angina pectoris, atrial fibrillation, cardiomyopathy, heart failure, deep vein thrombosis, hypotension, pulmonary embolism, renal artery thrombosis, syncope
	Everolimus	<i>Breast cancer, renal cell cancer, astrocytoma, PNET</i>		
	Temsirolimus	<i>Renal cell cancer</i>		
Differentiation agents	Tretinoin (ATRA)	<i>Acute promyelocytic leukemia</i>	Binds to nuclear receptors, decreasing proliferation and inducing differentiation of primitive promyelocytes	Peripheral and facial edema, arrhythmias, pericardial effusion/tamponade, myocardial ischemia and infarction, hypertension, cardiomyopathy, stroke, myocarditis, pericarditis, retinoic acid syndrome
	Arsenic trioxide			
	Vorinostat			
HDAC inhibitors	Romidepsin	<i>Cutaneous T-cell lymphoma</i>	Induces apoptosis of primitive promyelocytes via DNA fragmentation	Tachycardia, QTc prolongation, angina, hypotension. <b>BOX WARNING: QTc PROLONGATION, TdP, AND SCD</b>
	Panobinostat	<i>Multiple myeloma</i>		
		<i>Cutaneous and peripheral T-cell lymphoma</i>		
			Inhibits HDAC1, HDAC2, HDAC3, and HDAC6, resulting in the accumulation of acetyl groups, which alters chromatin structure and transcription factor activation, leading to cell growth arrest and apoptosis	Peripheral edema, QTc prolongation, hypotension, tachyarrhythmias, pulmonary embolism, hypertension. <b>BOX WARNING: SEVERE FATAL CARDIAC ISCHEMIC EVENTS AND ARRHYTHMIAS (panobinostat)</b>



## Prevention of Cancer Therapeutics-Induced Cardiotoxicity

Cardiotoxicity Stage	Level of Prevention	Goal of Prevention	Focus of Prevention	Means of Prevention
<b>A</b> <i>Cardiovascular Health</i>	PRIMORDIAL	Prevent Emergence of Cardiotoxicity Risk Factors	Patient and Provider Education	<ul style="list-style-type: none"> <li>• Best Practices and Guidelines</li> <li>• Continuing Medical Education</li> <li>• Public health education programs</li> </ul>
<b>B</b> <i>Cardiotoxicity Risk Factors</i>	PRIMARY	Prevent Occurrence of Cardiotoxicity	Risk Factor Modifying and Cardioprotective Strategies	<ul style="list-style-type: none"> <li>• Patient health education</li> <li>• Lifestyle modification</li> <li>• Cardioprotective cancer therapeutics</li> <li>• Cardioprotective cardiovascular pharmacotherapy</li> </ul>
<b>C</b> <i>Incipient Cardiotoxicity</i>	SECONDARY	Mitigate Progression of Cardiotoxicity	Early Diagnosis and Management	<ul style="list-style-type: none"> <li>• Cardiovascular diagnostic surveillance</li> <li>• Basic cardiovascular therapeutics</li> </ul>
<b>D</b> <i>Established Cardiotoxicity</i>	TERTIARY	Limit Debility from Cardiotoxicity	Late Management	<ul style="list-style-type: none"> <li>• Advanced cardiovascular therapeutics</li> <li>• Cardiovascular rehabilitation</li> </ul>

**Figure 1. Prevention of cancer therapeutics-induced cardiotoxicity.** Prevention of cancer therapeutics-induced cardiotoxicity.

which correspond with the stages of CTIC; each level of prevention has a particular goal, focus, and means (see [Figure 1](#)).

Primordial prevention is principally focused on the education of both patients and providers and on the implementation of general best practices to impede the emergence and development of risk factors for CTIC. This is being accomplished by the explosion of expert consensus guidelines in the last decade (see “expert consensus guidelines” below) as well as a growing presence of cardio-oncology programs in major oncology and cardiology scientific meetings. Moreover, there has been an increasing number of continuing medical education materials and public health education programs in this topic, all serving to raise awareness and educate on the cardiovascular effects of cancer therapies. Furthermore, the International Cardio-Oncology Society and the Canadian Cardiac Oncology Network have recently partnered in the writing of a cardio-oncology multidisciplinary training proposal to formally educate physicians in this developing field<sup>37</sup>.

Primary prevention has the goal of impeding the emergence of CTIC. The diagnosis and control of modifiable risk factors (see [Table 2](#)) and the promotion of cardiovascular health in the cancer population are of utmost importance. In addition, the administration of cardioprotective therapies to selected

patients with unavoidable moderate and high risk of CTIC is a means of primary prevention (see “cardioprotectants” below).

Secondary prevention is enforced once cardiac toxicity is incipient; early diagnosis and surveillance (see “blood biomarkers and diagnostic modalities” below), implementation of cardioprotective strategies, and administration of cardioprotective and basic therapies have the overarching goal to mitigate the progression of cardiotoxicity, restore cardiovascular health, and prevent complications. As in most health conditions, earlier diagnosis and treatment of CTIC seem to translate into improved outcomes<sup>38</sup>. Inspired by the American Society of Clinical Oncology (ASCO) clinical practice guideline on the prevention and monitoring of cardiac dysfunction in survivors of adult cancers<sup>5</sup>, as well as by other recent expert consensus guidelines that include recommendations on the prevention of CTIC<sup>8,32,39,40</sup>, we have constructed a table summarizing the general evidence-based recommendations for the prevention of cardiotoxicity before, during, and after cancer therapies (see [Table 3](#)).

Lastly, once CTIC has progressed sufficiently to be manifest in cardiovascular syndromes (e.g. HF, arrhythmias, acute coronary syndromes, etc.), tertiary prevention aims to limit further progression and disability, and promote rehabilitation, by both basic and advanced cardiovascular therapeutics. The evaluation

**Table 2. Risk factors of cancer therapeutics-induced cardiotoxicity.** CAD, coronary artery disease; CVD, cardiovascular disease; HF, heart failure; LVEF, left ventricular ejection fraction; RT, radiotherapy; SCD, sudden cardiac death; US FDA, United States Food and Drug Administration.

Risk factors of cancer therapeutics-induced cardiotoxicity			
Patient	Risk Factors of CVD	Health behaviors	Age
			Sex
			Smoking/tobacco use
			Overweight and obesity
		Health factors	Physical inactivity
			Poor nutrition
			Hypertension
			Diabetes mellitus
			Hyperlipidemia
		Risk factors of SCD	Metabolic syndrome
Kidney disease			
QTc prolongation			
Pre-existent CVD		Electrolyte abnormalities	
		Proarrhythmic drugs	
Cancer therapies	Cardiotoxic chemotherapy	High-dose anthracycline therapy	e.g. doxorubicin $\geq 250$ mg/m <sup>2</sup> or epirubicin $\geq 600$ mg/m <sup>2</sup>
		Low-dose anthracycline or trastuzumab therapy in high-risk patients	e.g. low normal LVEF (<53%), two or more general CVD risk factors, age 60 or over, established moderate to severe CVD
		Low-dose anthracycline and trastuzumab sequential therapy	e.g. doxorubicin <250 mg/m <sup>2</sup> or epirubicin <600 mg/m <sup>2</sup> + trastuzumab
		Other chemotherapy	e.g. US FDA box warning agents
	Cardiotoxic radiotherapy	High-dose cardiac radiation therapy	e.g. cardiac RT $\geq 30$ Gy or $\geq 2$ Gy/day
		Inability of cardiac avoidance	e.g. anterior or left chest radiation, tumor in cardiac proximity, lack of shielding, etc.
	Combination of cardiotoxic cancer therapies	Low-dose anthracycline + low-dose radiation therapy	e.g. doxorubicin <250 mg/m <sup>2</sup> or epirubicin <600 mg/m <sup>2</sup> + cardiac RT <30 Gy

and management of these defined CTIC syndromes are similar to those encountered in non-cancer patients. There are several clinical practice guidelines for the evaluation and management of these conditions in the literature<sup>31,35,36,41,42</sup>, and some specifically address the cancer population<sup>8,9</sup>; these tertiary prevention strategies will not be further detailed in this work.

**Expert panel consensus guidelines**

As mentioned above, the prevention of cardiotoxicity induced by cancer therapies has increasingly been the focus of several clinical cardiovascular and oncological societies, demonstrating the increasing relevance that this field has taken in the latest decade. In 2012, the European Society for Medical Oncology published a basic set of clinical practice guidelines for the prevention, monitoring, and management of CTIC<sup>40</sup>. The American

Society of Echocardiography and the European Society of Cardiovascular Imaging joined forces to create expert consensus guidelines for the multimodality imaging evaluation of cardiovascular complications of radiotherapy in adult patients in 2013<sup>30</sup> as well as evaluation during and after cancer therapies in 2014<sup>43</sup>. These efforts aim to standardize the indications, acquisition protocols, definitions, limitations, and vendor variability for the different cardiac imaging modalities usually employed in the diagnosis and surveillance of CTIC. In 2016, the American Heart Association (AHA) released a comprehensive scientific statement describing the mechanism, magnitude, onset, and likelihood of direct myocardial toxicity of several anti-cancer medications, among other clinically approved drugs, “to assist healthcare providers in improving the quality of care for these patients”<sup>77</sup>. In the same year, the Canadian Cardiovascular

**Table 3. Preventive strategies for cancer therapeutics-induced cardiotoxicity.** DM, diabetes mellitus; HL, hyperlipidemia; HTN, hypertension.

Preventive strategies for cancer therapeutics-induced cardiotoxicity		
Before cardiotoxic cancer therapy	Prioritize non-cardiotoxic cancer therapies without compromising cancer-specific outcomes	
	Diagnosis and control of modifiable cardiovascular risk factors (e.g. HTN, DM, HL, etc.)	
	Establish cardiovascular health (e.g. clinical examination, imaging, biomarkers)	
	Referral to specialist as appropriate	
During cardiotoxic cancer therapy	Diagnosis and control of modifiable cardiovascular risk factors (e.g. HTN, DM, HL, etc.)	
	Evaluate and maintain cardiovascular health (e.g. clinical examination, imaging, biomarkers)	
	Referral to specialist as appropriate	
	Cardiotoxic chemotherapy	Prioritize liposomal formulation and continuous infusion of doxorubicin
		Prioritize the use of dexrazoxane administration when considered appropriate (e.g. high-dose anthracyclines)
		Discontinue chemotherapy when considered appropriate
	Mediastinal radiotherapy	Prioritize lowest clinically effective radiation dose
		Deep-inspiration breath holding radiotherapy techniques
Intensity-modulated radiotherapy		
Discontinue radiotherapy when considered appropriate		
After cardiotoxic cancer therapy	Diagnosis and control of modifiable cardiovascular risk factors (e.g. HTN, DM, HL, etc.)	
	Monitor cardiovascular health (e.g. clinical examination, imaging, biomarkers)	
	Referral to specialist as appropriate	

Society published a set of best practice guidelines for the management of cancer patients, focusing on the identification of the high-risk population and the detection and prevention of cardiotoxicity<sup>39</sup>. This was followed by a position paper from the European Society of Cardiology summarizing the available evidence on the pathophysiology, prevention, diagnosis, therapeutic management, and long-term surveillance of the most common forms of cardiotoxicities induced by cancer therapies<sup>8</sup>. Most recently, as mentioned above, the ASCO published a clinical practice guideline outlining general recommendations for the prevention of cardiac dysfunction in survivors of adult cancers<sup>5</sup>. It was developed by an expert multidisciplinary physician panel using a systematic review (1996–2016) of 104 articles (meta-analyses, randomized clinical trials, and observational trials) and their clinical experience. Finally, the AHA has just published a scientific statement specifically and comprehensively dealing with the prevention of CVD in breast cancer patients, including that caused by cancer therapies<sup>32</sup>.

### Cardioprotectants

The development and investigation of cardioprotective agents has been exponentially increasing since the early days of anthracycline cardiotoxicity. To date, only one cardioprotectant is approved for clinical use, i.e. dexrazoxane; many others have been tested in the clinical setting, and an even larger number are on preclinical stages of investigation (see Table 4 for a succinct list of cardioprotective agents for CTIC that have been shown

to be useful at different stages of research). The vast majority of cardioprotectants have been tested in the setting of anthracycline administration, either alone or in combination with other chemotherapeutic agents; a small number has been tested in trastuzumab-only administration.

### Dexrazoxane

In the US, dexrazoxane is the only approved cardioprotective agent consistently shown to reduce the incidence or severity of AIC<sup>44</sup>. It is recommended to be given intravenously, in a 10:1 ratio of dexrazoxane:doxorubicin (e.g. dexrazoxane 500 mg/m<sup>2</sup>: doxorubicin 50 mg/m<sup>2</sup>) in the context of normal renal function; cardiac monitoring should be continued during dexrazoxane therapy<sup>17</sup>. Its use has been associated with statistically significant risk reductions for most doxorubicin-related cardiotoxic outcomes (other than survival)<sup>45</sup>, without compromising its therapeutic efficacy, in both pediatric and adult populations<sup>46–49</sup>. Although currently dexrazoxane use is strictly restricted to women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m<sup>2</sup> and need continued treatment to maintain tumor control<sup>44,50</sup>, its use in the treatment of other malignancies has been endorsed by expert guidelines<sup>51</sup>. Having said that, dexrazoxane is not currently recommended for routine use with the initiation of doxorubicin therapy for either primary or metastatic disease<sup>51–53</sup>. It needs to be noted that dexrazoxane was associated with a potential increased risk of acute myeloid leukemia, myelodysplastic syndrome, and second malignant neoplasms in a pediatric population with Hodgkin

**Table 4. Cardioprotectants in cancer therapeutics-induced cardiotoxicity.** ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; NSAID, non-steroidal anti-inflammatory drug; PC-SOD, lecithinized human recombinant super oxide dismutase.

Cardioprotectants in cancer therapeutics-induced cardiotoxicity			
Clinical	Antidotes	Dexrazoxane	Lipshultz <i>et al.</i> <sup>49</sup>
		N-acetylcysteine	Myers <i>et al.</i> <sup>54</sup>
	Beta-blockers	Carvedilol	Avila <i>et al.</i> <sup>55</sup>
		Nebivolol	Kaya <i>et al.</i> <sup>56</sup>
		Bisoprolol	Pituskin <i>et al.</i> <sup>57</sup>
		Metoprolol	Georgakopoulos <i>et al.</i> <sup>58</sup>
	ACEIs	Enalapril	Cardinale <i>et al.</i> <sup>59</sup>
		Ramipril	Jensen <i>et al.</i> <sup>60</sup>
		Perindopril	Pituskin <i>et al.</i> <sup>57</sup>
	ARBs	Valsartan	Nakamae <i>et al.</i> <sup>61</sup>
		Candesartan	Gulati <i>et al.</i> <sup>62</sup>
	MRA	Spirolactone	Akpek <i>et al.</i> <sup>63</sup>
	Statins	Atorvastatin	Acar <i>et al.</i> <sup>64</sup>
	Natural supplements	Melatonin	Lissoni <i>et al.</i> <sup>65</sup>
		Ubiquinone	Iarussi <i>et al.</i> <sup>66</sup>
		Vitamins C and E	Wagdi <i>et al.</i> <sup>67</sup>
Levocarnitine		Waldner <i>et al.</i> <sup>68</sup>	
Preclinical	ACEIs	Temocapril	Tokudome <i>et al.</i> <sup>69</sup>
		Delapril	Maeda <i>et al.</i> <sup>70</sup>
		Zofenopril	Sacco <i>et al.</i> <sup>71</sup>
	ARBs	Losartan	Matouk <i>et al.</i> <sup>72</sup>
	Statins	Fluvastatin	Riad <i>et al.</i> <sup>73</sup>
	Biguanides	Metformin	Kobashigawa <i>et al.</i> <sup>74</sup>
	Prostacyclins	Iloprost	Neilan <i>et al.</i> <sup>75</sup>
	NSAIDs	Meloxicam	Hassan <i>et al.</i> <sup>76</sup>
	Vasodilators	Diazoxide	Hole <i>et al.</i> <sup>77</sup>
		Molsidomine	Disli <i>et al.</i> <sup>78</sup>
		Nicorandil	Ahmed <i>et al.</i> <sup>79</sup>
	Iron salts	Ferric carboxymaltose	Toblli <i>et al.</i> <sup>80</sup>
	Neuropeptides	Ghrelin	Wang <i>et al.</i> <sup>81</sup>
	Natural antioxidants	Dihydromyricetin	Zhu <i>et al.</i> <sup>82</sup>
		Hydroxytyrosol	Granados-Principal <i>et al.</i> <sup>83</sup>
		Sesame oil	Saleem <i>et al.</i> <sup>84</sup>
Sesamin		Su <i>et al.</i> <sup>85</sup>	
Salidroside		Wang <i>et al.</i> <sup>86</sup>	
Glutathione		Mohamed <i>et al.</i> <sup>87</sup>	
Quercetin		Matouk <i>et al.</i> <sup>72</sup>	
Isorhamnetin		Sun <i>et al.</i> <sup>88</sup>	
Cannabidiol		Fouad <i>et al.</i> <sup>89</sup>	
Resveratrol		Dolinsky <i>et al.</i> <sup>90</sup>	
indole-3-carbinol	Hajra <i>et al.</i> <sup>91</sup>		
$\alpha$ -Linolenic acid	Yu <i>et al.</i> <sup>92</sup>		
Synthetic antioxidants	Didox	Al-Abd <i>et al.</i> <sup>93</sup>	
Other	Mdivi-1	Gharanei <i>et al.</i> <sup>94</sup>	

lymphoma in a single study a decade ago<sup>95</sup>. Many later studies have not been able to reproduce these initial results<sup>45,96–98</sup>. Furthermore, a recent large clinical trial in a pediatric population corroborated these latter findings, suggesting that dexrazoxane was indeed cardioprotective, did not interfere with antitumor efficacy, did not result in an increased occurrence of toxicities, and had no association with a significant rise in second malignancies<sup>99</sup>.

### Cardiovascular pharmacotherapy

Given their consistent benefit in other cardiovascular conditions (e.g. HF and CAD), beta-blockers, angiotensin converting-enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), mineralocorticoid receptor antagonists (MRAs), and HMG-CoA reductase inhibitors (statins) have been extensively studied in the clinical setting, in the context of both anthracycline and trastuzumab therapy, for the prevention of LV dysfunction.

Beta-blocker agents with antioxidant properties such as carvedilol<sup>100–102</sup> and nebivolol<sup>56</sup> have shown the most promising results in early small clinical trials investigating their cardioprotective effects. Regrettably, in the so far largest clinical trial of beta-blockers for the prevention of cardiotoxicity under contemporary anthracycline dosage, carvedilol monotherapy had no impact on the incidence of early onset of LV ejection fraction (LVEF) reduction when compared to placebo in a breast cancer population<sup>55</sup>. Similarly, ACEI monotherapy with enalapril<sup>59</sup> and ramipril<sup>60</sup> has also been shown to be beneficial in early small clinical trials; however, the administration of enalapril monotherapy either before chemotherapy or during or after chemotherapy in selected patients with elevated serum troponin levels failed to have a significant impact on outcomes in the most recent multicenter clinical trial<sup>103</sup>. As for ARBs, valsartan was shown to be beneficial in small clinical trials over a decade ago<sup>61</sup>; however, the use of candesartan as a cardioprotectant has recently provided conflicting results in well-conducted randomized placebo-controlled clinical trials<sup>62,104</sup>. The cardioprotective effects of spironolactone monotherapy have also been promising in early small clinical settings<sup>63</sup>, but data from larger randomized clinical trials are still lacking.

Several clinical trials have investigated the cardioprotective effects of combined neurohormonal inhibition, i.e. beta-blockers plus ACEIs/ARBs, as is recommended in the general population with HF<sup>34</sup>. Over a decade ago, early initiation of combined beta-blockers and ACEIs was shown to provide benefit in a small population of established AIC, albeit the effect was thought to be mediated mainly by beta-blockers<sup>105</sup>. Since then, the role of combined neurohormonal inhibition in cardioprotection has been repeatedly evaluated up to this day in the settings of anthracycline, trastuzumab, or sequential chemotherapy. In the only positive trial to date, the combination of enalapril and carvedilol was shown to prevent deterioration of LV function in adult patients with hematological malignancies undergoing anthracycline therapy<sup>106</sup>. However, there are significant concerns regarding this trial, including lack of blinding and differing results based on the methods used to quantify LVEF, making

it difficult to conclusively interpret<sup>107</sup>. In other clinical settings, metoprolol has been tested in combination with enalapril<sup>58</sup> and with candesartan<sup>62</sup>, with disappointing results. Similarly, the combination of bisoprolol and perindopril failed to prevent trastuzumab-induced LV remodeling in a modern cohort of ERBB-positive breast cancer patients<sup>57</sup>. Finally, in the as-yet-unpublished work by Guglin *et al.* presented at the 2018 American College of Cardiology annual meeting, both lisinopril and carvedilol failed to prevent cardiotoxicity in breast cancer patients treated with trastuzumab monotherapy, whereas both drugs prevented cardiotoxicity in patients who received both anthracycline and trastuzumab sequential therapy<sup>108</sup>.

The cardioprotective role of statins has also been evaluated in small retrospective and prospective analyses, both with non-specific statins<sup>109,110</sup> and atorvastatin monotherapy<sup>64</sup>, and was found to be beneficial. These findings are very promising but are yet to be corroborated in larger randomized placebo-controlled trials (simvastatin NCT02096588; atorvastatin NCT02674204).

### Natural supplements

Clinical cardioprotective data involving natural supplements are scarce but growing. Ubiquinone (coenzyme Q10) administration in children receiving anthracyclines was associated with a lesser degree of LV dysfunction and remodeling<sup>66</sup>. N-acetylcysteine, administered either alone or with vitamins E and C, averted LV dysfunction from developing in patients receiving high-dose doxorubicin and/or radiotherapy, respectively<sup>54,67</sup>. Melatonin<sup>65</sup> and levocarnitine<sup>68</sup> have also been tested in the clinical setting with positive results. Larger randomized placebo-controlled trials are lacking as to draw firm conclusions relevant to the clinical practice.

### Preclinical agents

Many other agents have been shown to ameliorate anthracycline cardiotoxicity in small animal models of CTIC. Clinically available agents such as losartan<sup>72</sup>, fluvastatin<sup>73</sup>, metformin<sup>74</sup>, iloprost<sup>75</sup>, and meloxicam<sup>76</sup> as well as other clinically unavailable ACEIs<sup>69–71</sup> have been shown to have cardioprotective results *in vivo*. Vasodilators<sup>77–79</sup>, neuropeptides<sup>81</sup>, and iron salts<sup>80</sup> have also been found to be useful. Finally, given that the pathogenesis of anthracyclines is in part related to increased oxidative stress<sup>100</sup>, several natural antioxidants (e.g. sesamin<sup>85</sup> and sesame oil<sup>84</sup> and hydroxytyrosol<sup>83</sup>, among others<sup>82,86–92</sup>) have been tested and shown various degrees of cardioprotective effects. Didox, a synthetic antioxidant, was also shown to significantly potentiate the cytotoxicity of doxorubicin in liver cancer cells while at the same time protecting the murine model from cardiotoxicity<sup>93</sup>. Mdivi-1, a mitochondrial division/mitophagy inhibitor, was also shown to lessen AIC<sup>94</sup>.

### Other cardioprotective strategies

Within a family of cardiotoxic agents, there are variations in terms of cardiac safety. For example, the use of pegylated liposomal doxorubicin has been associated with a lower incidence of CTIC and HF<sup>111,112</sup>. Similarly, epirubicin or mitoxantrone are also believed to cause less cardiotoxicity compared with doxorubicin<sup>113</sup>. When considering the large family of

multitargeted tyrosine kinase inhibitors, vandetanib, nilotinib, and ponatinib seem to possess the highest cardiotoxicity risk<sup>17</sup>. The role of exercise therapy in the prevention of CTIC remains controversial because of conflicting results<sup>114,115</sup>.

In summary, with the exception of dexrazoxane, no conclusive recommendations can be made on the clinical use of cardioprotectants for either stage B or stage C CTIC<sup>5</sup>.

**Blood biomarkers**

Blood biomarkers, in particular myocardial natriuretic peptides (i.e. NTproBNP and BNP) and sarcomeric proteins

(i.e. troponin I and T), have been an integral part of the diagnostic and prognostic armamentarium in common cardiovascular conditions, such as HF and CAD. As it would seem natural, they have been progressively adopted in clinical practice to assist in the diagnosis or surveillance of patients with incipient and established CTIC, in particular LV dysfunction and HF (see Table 5 for a list of various clinical and preclinical biomarkers shown to predict CTIC)<sup>5</sup>.

Troponin I<sup>59,116,117</sup> and troponin T<sup>118</sup> have been shown to be clinically useful in several clinical trials of cardiotoxicity prediction. Modern, more-sensitive assays of troponin I and T

**Table 5. Blood biomarkers in cancer therapeutics-induced cardiotoxicity.** ANP, atrial natriuretic peptide; BNP, B-type natriuretic peptide; cMLC1, cardiac myosin light chain-1; cTnAAbs, cardiac troponin specific autoantibodies; cTnI, cardiac troponin I; cTnT, cardiac troponin T; GWAS, genome-wide association study; hs-CRP, high-sensitive C-reactive protein; hs-TnI, high-sensitive troponin I; GDF15, growth differentiation factor-15; GPBB, glycogen phosphorylase BB; IMA, ischemia modified albumin; MPO, myeloperoxidase; NTproBNP, amino-terminal pro B-type natriuretic peptide; PIGF, placental-derived growth factor; ROS, reactive oxygen species.

Blood biomarkers in cancer therapeutics-induced cardiotoxicity			
Clinical	Myocardial natriuretic peptides	NTproBNP	De Iulius <i>et al.</i> <sup>119</sup>
		BNP	Lenihan <i>et al.</i> <sup>37</sup>
		ANP	Nousiainen <i>et al.</i> <sup>120</sup>
	Myocardial sarcomere proteins	cTnI	Cardinale <i>et al.</i> <sup>117</sup>
		cTnT	Killickap <i>et al.</i> <sup>118</sup>
		hs-cTnI	Sawaya <i>et al.</i> <sup>121</sup>
		hs-cTnT	Katsurada <i>et al.</i> <sup>122</sup>
		us-cTnI	Ky <i>et al.</i> <sup>123</sup>
		cTnAAbs	Ylänen <i>et al.</i> <sup>124</sup>
	Other biomarkers	Hb	Garrone <i>et al.</i> <sup>125</sup>
		hsCRP	Onitilo <i>et al.</i> <sup>126</sup>
		MPO	Ky <i>et al.</i> <sup>123</sup>
		PIGF	Putt <i>et al.</i> <sup>127</sup>
		GDF15	Arslan <i>et al.</i> <sup>128</sup>
		Arginine-NO metabolites	Finkelman <i>et al.</i> <sup>129</sup>
		GPBB	Horacek <i>et al.</i> <sup>130</sup>
		ROS	Mercuro <i>et al.</i> <sup>131</sup>
		IMA	Ma <i>et al.</i> <sup>132</sup>
	Single nucleotide polymorphisms (GWAS)	rs2229774	Aminkeng <i>et al.</i> <sup>133</sup>
		rs1786814	Wang <i>et al.</i> <sup>134</sup>
rs28714259		Schneider <i>et al.</i> <sup>135</sup>	
Preclinical	DNA	Doxorubicin DNA adducts	Hahm <i>et al.</i> <sup>136</sup>
		Spp1, Fhl1, Timp1, Ccl7 and Reg3b	Mori <i>et al.</i> <sup>137</sup>
	MicroRNA	miR-34a	Desai <i>et al.</i> <sup>138</sup>
		miR-34c	Vacchi-Suzzi <i>et al.</i> <sup>139</sup>
		miR-146a	Horie <i>et al.</i> <sup>140</sup>
	Proteins	S100A1	Eryilmaz <i>et al.</i> <sup>141</sup>
		cMLC1	EIzarrad <i>et al.</i> <sup>142</sup>
		Cathepsin B	Bao <i>et al.</i> <sup>143</sup>
	Proteomics pattern diagnostics		Petricoin <i>et al.</i> <sup>144</sup>
	Metabolomics pattern diagnostics		Li <i>et al.</i> <sup>145</sup>
Transcriptome profiling		Todorova <i>et al.</i> <sup>146</sup>	

(high-sensitivity and ultra-sensitivity) have also been shown to be clinically predictive of CTIC<sup>121–123</sup>. Early studies have suggested that troponin I elevation predicted severity of CTIC<sup>116,117</sup>, and refractoriness to HF therapy in the case of trastuzumab-induced cardiomyopathy<sup>117</sup>, but response to enalapril monotherapy in the case of AIC<sup>59</sup>. However, in a recent large multicenter randomized clinical trial, these findings could not be corroborated<sup>103</sup>. Interestingly, the presence of troponin-specific autoantibodies also predicted cardiac dysfunction by cardiac magnetic resonance (CMR) imaging in the absence of elevated traditional troponin levels<sup>124</sup>. Myocardial natriuretic peptides, such as NTproBNP<sup>119</sup>, BNP<sup>147</sup>, and ANP<sup>120</sup>, have also been shown to be clinically useful predictors of CTIC, albeit to a lesser extent.

Although the use of these blood biomarkers is currently recommended in the evaluation and surveillance of patients with CTIC<sup>5,8</sup>, their helpfulness remains disputed owing to inconsistent results in terms of sensitivity, accuracy, and reliability<sup>148</sup>. Hence, various other alternative blood biomarkers have been studied in recent years, either alone or in combination, and shown also to be clinically predictive of CTIC, e.g. hsCRP<sup>126</sup>, MPO<sup>123</sup>, and arginine-NO metabolites (arginine, citrulline, ornithine, asymmetric dimethylarginine, symmetric dimethylarginine, and N-monomethylarginine)<sup>129</sup>, among others<sup>125,127,128,130–132</sup>. Likewise, many other predictive biomarker strategies are currently being developed in the preclinical arena. Proteomics<sup>144</sup> and metabolomics<sup>145</sup> pattern diagnostics, as well as transcriptome profiling<sup>146</sup>, have been shown to be useful in animal models of AIC as well as the detection of doxorubicin DNA adducts (HM-dUMP, 8-OH-dGMP, HM-dCMP, and Me-dCMP)<sup>136</sup> and other particular genes that are overexpressed during incipient cardiotoxicity<sup>137</sup>. Cellular proteins such as S100A1<sup>141</sup>, cMLC1<sup>142</sup>, and cathepsin B<sup>143</sup> have also been shown to have predictive value. Some microRNAs (e.g. miR-34a<sup>138</sup>, miR-34c<sup>139</sup>, and miR-146a<sup>140</sup>) have been shown to be useful in predicting CTIC in small animal models; however, a recent clinical trial involving miR-208a measurement in breast cancer patients failed to have a predictive impact<sup>149</sup>.

Finally, research efforts to identify the genetic susceptibility of AIC have been increasing in the last decade, with the purpose of risk stratifying patients before they receive anthracycline chemotherapy. To date, three main single-nucleotide polymorphisms (SNPs: rs28714259<sup>135</sup>, rs1786814<sup>134</sup>, and rs2229774<sup>133</sup>) have been identified as being strongly associated with AIC by means of genome-wide association studies (GWAS) from pediatric and adult case-controlled clinical trial populations.

### Diagnostic modalities

Non-blood diagnostic modalities are also an integral part of the evaluation of CVDs. For the purpose of early diagnosis and surveillance of CTIC, several imaging modalities have been studied since the late 1970s and shown to be of value (see Table 6). Historically, electrocardiography<sup>150</sup> was used to diagnose arrhythmias during anthracycline infusion, and radionuclide cineangiography (MUGA)<sup>151,152</sup> was the first technique used to detect falls in LV systolic function in patients receiving anthracyclines<sup>153</sup>. Although MUGA is still considered

widely available and highly reproducible, it carries the main disadvantage of submitting cancer patients to small, but potentially significant, radiation exposure (5–10 mSv)<sup>30,43</sup>. Additionally, 2D-echocardiogram<sup>154</sup> and stress 2D-echocardiogram<sup>155</sup> have been shown to be beneficial in the serial evaluation of cancer patients undergoing cardiotoxic chemotherapies. Newer echocardiographic modalities, such as 3D-echocardiography<sup>156</sup> and LV global longitudinal strain (LVGLS) measurement by speckle-tracking echocardiography (STE)<sup>157</sup>, have demonstrated superiority over 2D-echocardiography in terms of reproducibility and predictability, respectively. CMR is currently considered the gold standard modality in the assessment of LV and right ventricular volumes and function<sup>158</sup>. Secondary modalities such as CMR strain imaging<sup>159</sup>, T1 mapping<sup>160</sup>, and extracellular volume fraction (ECV)<sup>161</sup> have also been clinically studied in recent years and found to be of great value in the assessment of subclinical cardiotoxicity. Among various non-imaging techniques, cardiopulmonary exercise testing was shown to detect abnormalities in peak oxygen consumption in cancer patients with apparently normal LV function<sup>162</sup>, suggesting subclinical impairments of contractile reserve and chronotropic incompetence<sup>28</sup>. Finally, many other imaging modalities are currently being studied in the preclinical arena to help detect incipient cardiotoxicity with high specificity and sensitivity. For example, 18F-labeled tetrapeptide caspase positron emission tomography (PET) is able to specifically diagnose doxorubicin-induced myocardial apoptosis in a murine model by detection of overexpressed myocardial caspase 3 resulting from anthracycline chemotherapy<sup>163</sup>.

According to current guidelines, echocardiography (ideally 3D-echocardiography) is the method of choice for the evaluation of patients before, during, and after cancer therapies<sup>43</sup>. CMR and MUGA scan (in that order) should be utilized as alternative modalities whenever the echocardiographic image quality is deficient<sup>5</sup>. When available, measurement of LVGLS by STE is also recommended as a complementary modality<sup>5</sup>. CMR should also be considered for the evaluation of chronic “constrictive” pericarditis, when the diagnosis remains uncertain after a careful echocardiographic evaluation<sup>43</sup>.

To date, there is little evidence to guide the indication, timing, and frequency of use of imaging modalities in patients undergoing cancer therapies. The ASCO expert consensus recommends an echocardiographic evaluation prior to the initiation of potentially cardiotoxic cancer therapies<sup>5</sup>. Routine imaging surveillance in asymptomatic patients should be offered to patients based on the healthcare provider’s perceived risk of CTIC, and the frequency of it needs to be individualized based on clinical judgment and patient circumstances<sup>5</sup>. Subsequent to cardiotoxic cancer therapies, it is recommended that high-risk patients undergo a follow up LVEF evaluation between 6 and 12 months after completion of therapy<sup>5</sup>.

### Conclusions

In this work, we have attempted to comprehensively and concisely survey the most relevant available literature pertaining to cardioprotection during cancer therapy. We have briefly

**Table 6. Diagnostic modalities in cancer therapeutics-induced cardiotoxicity.** 2D, two-dimensional; 3D, three-dimensional; 99m Tc, technetium-99; CMR, cardiac magnetic resonance; CPET, cardiopulmonary exercise testing; ECG, electrocardiogram; ECV, extracellular volume fraction; LVEF, left ventricular ejection fraction; LVGLS, left ventricular global longitudinal strain; MUGA, multigated acquisition; PET, positron emission tomography; RBC, red blood cells.

Diagnostic modalities in cancer therapeutics-induced cardiotoxicity		
Established clinical	ECG	Steinberg <i>et al.</i> <sup>150</sup>
	MUGA (99m Tc-labeled RBC)	Schwartz <i>et al.</i> <sup>151</sup>
	Stress MUGA	McKillop <i>et al.</i> <sup>152</sup>
	2D-echocardiography	Thavendiranathan <i>et al.</i> <sup>154</sup>
	Stress 2D-echocardiography	Khouri <i>et al.</i> <sup>155</sup>
	CPET	Jones <i>et al.</i> <sup>162</sup>
Novel clinical	3D-echocardiography	Walker <i>et al.</i> <sup>156</sup>
	Speckle-tracking echocardiography (LVGLS)	Negishi <i>et al.</i> <sup>157</sup>
	CMR	Armstrong <i>et al.</i> <sup>158</sup>
	CMR strain imaging	Drafts <i>et al.</i> <sup>159</sup>
	CMR T1 mapping	Lightfoot <i>et al.</i> <sup>160</sup>
	CMR ECV	Jordan <i>et al.</i> <sup>161</sup>
Preclinical	PET (18F-labeled tetrapeptidic caspase)	Su <i>et al.</i> <sup>163</sup>

summarized the pathophysiology of CTIC, describing the mechanisms of cardiotoxicity of various agents, and risk factors that promote this phenomenon. For didactic purposes, we have classified CTIC into four progressive stages, in which four levels of prevention are applied, each having a specific goal, focus, and means of prevention. We have subsequently reviewed the available data on cardioprotective agents, blood biomarkers, and imaging diagnostic modalities, which are the core of primary and secondary prevention strategies. Finally, we have provided general evidence-based preventive recommendations for CTIC following the most current expert consensus guidelines. The promotion of the cardiovascular health of cancer patients and

cancer survivors is paramount, requiring the diligent and knowledgeable effort of a multidisciplinary team of healthcare providers; as in all medical disorders, prevention is better than cure.

#### Grant information

W. H. Wilson Tang is supported by grants from the National Institutes of Health (R01HL103866, P20HL113452, R01DK106000, and R01HL126827).

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

#### References



1. Miller KD, Siegel RL, Lin CC, *et al.*: **Cancer treatment and survivorship statistics, 2016.** *CA Cancer J Clin.* 2016; **66**(4): 271–89.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
2. Patnaik JL, Byers T, DiGiuseppe C, *et al.*: **Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study.** *Breast Cancer Res.* 2011; **13**(3): R64.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Tashakkor AY, Moghaddamjou A, Chen L, *et al.*: **Predicting the risk of cardiovascular comorbidities in adult cancer survivors.** *Curr Oncol.* 2013; **20**(5): e360–70.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Oeffinger KC, Mertens AC, Sklar CA, *et al.*: **Chronic health conditions in adult survivors of childhood cancer.** *N Engl J Med.* 2006; **355**(15): 1572–82.  
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Armenian SH, Lacchetti C, Barac A, *et al.*: **Prevention and Monitoring of**  
**Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.** *J Clin Oncol.* 2017; **35**(8): 893–911.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
6. Jaworski C, Mariani JA, Wheeler G, *et al.*: **Cardiac complications of thoracic irradiation.** *J Am Coll Cardiol.* 2013; **61**(23): 2319–28.  
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Page RL 2nd, O'Bryant CL, Cheng D, *et al.*: **Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association.** *Circulation.* 2016; **134**(6): e32–69.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
8. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, *et al.*: **2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).** *Eur Heart J.* 2016; **37**(36): 2768–801.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)



9. Finet JE: Management of Heart Failure in Cancer Patients and Cancer Survivors. *Heart Fail Clin.* 2017; 13(2): 253–88.  
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Jones LW, Haykowsky MJ, Swartz JJ, et al.: Early breast cancer therapy and cardiovascular injury. *J Am Coll Cardiol.* 2007; 50(15): 1435–41.  
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Von Hoff DD, Layard MW, Basa P, et al.: Risk factors for doxorubicin-induced congestive heart failure. *Ann Intern Med.* 1979; 91(5): 710–7.  
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Dindogru A, Barcos M, Henderson ES, et al.: Electrocardiographic changes following adriamycin treatment. *Med Pediatr Oncol.* 1978; 5(1): 65–71.  
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Steinherz LJ, Steinherz PG, Tan CT, et al.: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. *JAMA.* 1991; 266(12): 1672–7.  
[PubMed Abstract](#) | [Publisher Full Text](#)
14. Temming P, Qureshi A, Hardt J, et al.: Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: retrospective cohort study in a single centre in the United Kingdom. *Pediatr Blood Cancer.* 2011; 56(4): 625–30.  
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Armenian SH, Mertens L, Slorach C, et al.: Prevalence of anthracycline-related cardiac dysfunction in long-term survivors of adult-onset lymphoma. *Cancer.* 2018; 124(4): 850–7.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
16. Oliveira GH, Hardaway BW, Kucheryavaya AY, et al.: Characteristics and survival of patients with chemotherapy-induced cardiomyopathy undergoing heart transplantation. *J Heart Lung Transplant.* 2012; 31(8): 805–10.  
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Wolters Kluwer Clinical Drug Information. Inc. (Lexi-Drugs). Wolters Kluwer Drug Information, Inc. Last accessed May 27th, 2018.  
[Reference Source](#)
18. Kerkelä R, Grazette L, Yacobi R, et al.: Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. *Nat Med.* 2006; 12(8): 908–16.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
19. Chu TF, Rupnick MA, Kerkela R, et al.: Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. *Lancet.* 2007; 370(9604): 2011–9.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
20. Ewer MS, Vooletich MT, Durand JB, et al.: Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. *J Clin Oncol.* 2005; 23(31): 7820–6.  
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Lal H, Kolaja KL, Force T: Cancer genetics and the cardiotoxicity of the therapeutics. *J Am Coll Cardiol.* 2013; 61(3): 267–74.  
[PubMed Abstract](#) | [Publisher Full Text](#)
22. Galper SL, Yu JB, Mauch PM, et al.: Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. *Blood.* 2011; 117(2): 412–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
23. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al.: Late cardiotoxicity after treatment for Hodgkin lymphoma. *Blood.* 2007; 109(5): 1878–86.  
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Hoening MJ, Botma A, Aleman BM, et al.: Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. *J Natl Cancer Inst.* 2007; 99(5): 365–75.  
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Nilsson G, Holmberg L, Garmo H, et al.: Distribution of coronary artery stenosis after radiation for breast cancer. *J Clin Oncol.* 2012; 30(4): 380–6.  
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Heidenreich PA, Hancock SL, Vagelos RH, et al.: Diastolic dysfunction after mediastinal irradiation. *Am Heart J.* 2005; 150(5): 977–82.  
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Armstrong GT, Joshi VM, Ness KK, et al.: Comprehensive Echocardiographic Detection of Treatment-Related Cardiac Dysfunction in Adult Survivors of Childhood Cancer: Results From the St. Jude Lifetime Cohort Study. *J Am Coll Cardiol.* 2015; 65(23): 2511–22.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Groarke JD, Tanguturi VK, Hainer J, et al.: Abnormal exercise response in long-term survivors of hodgkin lymphoma treated with thoracic irradiation: evidence of cardiac autonomic dysfunction and impact on outcomes. *J Am Coll Cardiol.* 2015; 65(6): 573–83.  
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Heidenreich PA, Hancock SL, Lee BK, et al.: Asymptomatic cardiac disease following mediastinal irradiation. *J Am Coll Cardiol.* 2003; 42(4): 743–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Lancellotti P, Nkomo VT, Badano LP, et al.: Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. *Eur Heart J Cardiovasc Imaging.* 2013; 14(8): 721–40.  
[PubMed Abstract](#) | [Publisher Full Text](#)
31. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, et al.: 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation.* 2013; 128(16): e240–327.  
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Mehta LS, Watson KE, Barac A, et al.: Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. *Circulation.* 2018; 137(8): e30–e66.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
33. Benjamin EJ, Virani SS, Callaway CW, et al.: Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association. *Circulation.* 2018; 137(12): e67–e492.  
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Yancy CW, Jessup M, Bozkurt B, et al.: 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *J Am Coll Cardiol.* 2017; 70(6): 776–803.  
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Nishimura RA, Otto CM, Bonow RO, et al.: 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2014; 63(22): e57–185.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
36. Zipes DP, Camm AJ, Borggrefe M, et al.: ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death); developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. *Circulation.* 2006; 114(10): e385–484.  
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Lenihan DJ, Hartlage G, DeCara J, et al.: Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty. *J Card Fail.* 2016; 22(6): 465–71.  
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Cardinale D, Colombo A, Bacchiani G, et al.: Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. *Circulation.* 2015; 131(22): 1981–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Virani SA, Dent S, Brezden-Masley C, et al.: Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy. *Can J Cardiol.* 2016; 32(7): 831–41.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
40. Curigliano G, Cardinale D, Suter T, et al.: Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. *Ann Oncol.* 2012; 23 Suppl 7: vii155–66.  
[PubMed Abstract](#) | [Publisher Full Text](#)
41. Fuster V, Rydén LE, Cannom DS, et al.: 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation.* 2011; 123(10): e269–367.  
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Adler Y, Charron P, Imazio M, et al.: 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J.* 2015; 36(42): 2921–64.  
[PubMed Abstract](#) | [Publisher Full Text](#)
43. Plana JC, Galderisi M, Barac A, et al.: Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr.* 2014; 27(9): 911–39.  
[PubMed Abstract](#) | [Publisher Full Text](#)
44. FDA Statement on Dextrazoxane (07-09-2011).  
[Reference Source](#)
45. Shaikh F, Dupuis LL, Alexander S, et al.: Cardioprotection and Second Malignant Neoplasms Associated With Dextrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis. *J Natl Cancer Inst.* 2015; 108(4): pii: djv357.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
46. Venturini M, Michelotti A, Del Mastro L, et al.: Multicenter randomized controlled clinical trial to evaluate cardioprotection of dextrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. *J Clin Oncol.* 1996; 14(12): 3112–20.  
[PubMed Abstract](#) | [Publisher Full Text](#)
47. Marty M, Espié M, Llombart A, et al.: Multicenter randomized phase III study of the cardioprotective effect of dextrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. *Ann Oncol.* 2006; 17(4): 614–22.  
[PubMed Abstract](#) | [Publisher Full Text](#)

48. Choi HS, Park ES, Kang HJ, *et al.*: **Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.** *J Korean Med Sci.* 2010; **25**(9): 1336–42.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
49. Lipshultz SE, Rifai N, Dalton VM, *et al.*: **The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.** *N Engl J Med.* 2004; **351**(2): 145–53.  
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Swain SM, Whaley FS, Gerber MC, *et al.*: **Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.** *J Clin Oncol.* 1997; **15**(4): 1333–40.  
[PubMed Abstract](#) | [Publisher Full Text](#)
51. Hensley ML, Hagerty KL, Kewalramani T, *et al.*: **American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.** *J Clin Oncol.* 2009; **27**(1): 127–45.  
[PubMed Abstract](#) | [Publisher Full Text](#)
52. FDA Drug Safety: **Zincard.** 2012.  
[Reference Source](#)
53. Swain SM, Whaley FS, Gerber MC, *et al.*: **Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.** *J Clin Oncol.* 1997; **15**(4): 1318–32.  
[PubMed Abstract](#) | [Publisher Full Text](#)
54. Myers C, Bonow R, Palmeri S, *et al.*: **A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine.** *Semin Oncol.* 1983; **10**(1 Suppl 1): 53–5.  
[PubMed Abstract](#)
55. **F** Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, *et al.*: **Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECY Trial.** *J Am Coll Cardiol.* 2018; **71**(20): 2281–90.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
56. Kaya MG, Ozkan M, Gunebakmaz O, *et al.*: **Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study.** *Int J Cardiol.* 2013; **167**(5): 2306–10.  
[PubMed Abstract](#) | [Publisher Full Text](#)
57. **F** Pituskin E, Mackey JR, Koshman S, *et al.*: **Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.** *J Clin Oncol.* 2017; **35**(8): 870–7.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
58. Georgakopoulos P, Roussou P, Matsakas E, *et al.*: **Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up.** *Am J Hematol.* 2010; **85**(11): 894–6.  
[PubMed Abstract](#) | [Publisher Full Text](#)
59. Cardinale D, Colombo A, Sandri MT, *et al.*: **Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.** *Circulation.* 2006; **114**(23): 2474–81.  
[PubMed Abstract](#)
60. Jensen BV, Nielsen SL, Skovsgaard T: **Treatment with angiotensin-converting enzyme inhibitor for epirubicin-induced dilated cardiomyopathy.** *Lancet.* 1996; **347**(8997): 297–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
61. Nakamae H, Tsumura K, Terada Y, *et al.*: **Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone.** *Cancer.* 2005; **104**(11): 2492–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
62. **F** Gulati G, Heck SL, Ree AH, *et al.*: **Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.** *Eur Heart J.* 2016; **37**(21): 1671–80.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
63. **F** Akpek M, Ozdogru I, Sahin O, *et al.*: **Protective effects of spironolactone against anthracycline-induced cardiomyopathy.** *Eur J Heart Fail.* 2015; **17**(1): 81–9.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
64. Acar Z, Kale A, Turgut M, *et al.*: **Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy.** *J Am Coll Cardiol.* 2011; **58**(9): 988–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
65. Lissoni P, Barni S, Mandalà M, *et al.*: **Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status.** *Eur J Cancer.* 1999; **35**(12): 1688–92.  
[PubMed Abstract](#) | [Publisher Full Text](#)
66. Iarussi D, Auricchio U, Agretto A, *et al.*: **Protective effect of coenzyme Q<sub>10</sub> on anthracyclines cardiotoxicity: Control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma.** *Mol Aspects Med.* 1994; **15** Suppl: s207–12.  
[PubMed Abstract](#) | [Publisher Full Text](#)
67. Wagdi P, Rouvinez G, Fluri M, *et al.*: **Kardioprotektion bei Chemo- und Radiotherapie für maligne Erkrankungen—eine echokardiographische Pilotstudie.** *Praxis (Bern 1994).* 1995; **84**: 1220–3.
68. Waldner R, Laschan C, Lohninger A, *et al.*: **Effects of doxorubicin-containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma.** *J Cancer Res Clin Oncol.* 2006; **132**(2): 121–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
69. Tokudome T, Mizushige K, Noma T, *et al.*: **Prevention of doxorubicin (adriamycin)-induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by acoustic densitometry.** *J Cardiovasc Pharmacol.* 2000; **36**(3): 361–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
70. Maeda A, Honda M, Kuramochi T, *et al.*: **An angiotensin-converting enzyme inhibitor protects against doxorubicin-induced impairment of calcium handling in neonatal rat cardiac myocytes.** *Clin Exp Pharmacol Physiol.* 1997; **24**(9–10): 720–6.  
[PubMed Abstract](#) | [Publisher Full Text](#)
71. Sacco G, Bigioni M, Evangelista S, *et al.*: **Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat.** *Eur J Pharmacol.* 2001; **414**(1): 71–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
72. Matouk AI, Taye A, Heeba GH, *et al.*: **Quercetin augments the protective effect of losartan against chronic doxorubicin cardiotoxicity in rats.** *Environ Toxicol Pharmacol.* 2013; **36**(2): 443–50.  
[PubMed Abstract](#) | [Publisher Full Text](#)
73. Riad A, Bien S, Westermann D, *et al.*: **Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice.** *Cancer Res.* 2009; **69**(2): 695–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
74. Kobashigawa LC, Xu YC, Padbury JF, *et al.*: **Metformin protects cardiomyocyte from doxorubicin induced cytotoxicity through an AMP-activated protein kinase dependent signaling pathway: an *in vitro* study.** *PLoS One.* 2014; **9**(8): e104888.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
75. Neilan TG, Jassal DS, Scully MF, *et al.*: **Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression.** *Eur Heart J.* 2006; **27**(10): 1251–6.  
[PubMed Abstract](#) | [Publisher Full Text](#)
76. Hassan MH, El-Beshbishy HA, Aly H, *et al.*: **Modulatory effects of meloxicam on cardiotoxicity and antitumor activity of doxorubicin in mice.** *Cancer Chemother Pharmacol.* 2014; **74**(3): 559–69.  
[PubMed Abstract](#) | [Publisher Full Text](#)
77. Hole LD, Larsen TH, Fossan KO, *et al.*: **Diazoxide protects against doxorubicin-induced cardiotoxicity in the rat.** *BMC Pharmacol Toxicol.* 2014; **15**: 28.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
78. Disli OM, Sarihan E, Colak MC, *et al.*: **Effects of molsidomine against doxorubicin-induced cardiotoxicity in rats.** *Eur Surg Res.* 2013; **51**(1–2): 79–90.  
[PubMed Abstract](#) | [Publisher Full Text](#)
79. Ahmed LA, El-Maraghy SA: **Nicorandil ameliorates mitochondrial dysfunction in doxorubicin-induced heart failure in rats: possible mechanism of cardioprotection.** *Biochem Pharmacol.* 2013; **86**(9): 1301–10.  
[PubMed Abstract](#) | [Publisher Full Text](#)
80. Toblli JE, Rivas C, Cao G, *et al.*: **Ferric carboxymaltose-mediated attenuation of Doxorubicin-induced cardiotoxicity in an iron deficiency rat model.** *Chemother Res Pract.* 2014; **2014**: 570241.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
81. Wang X, Wang XL, Chen HL, *et al.*: **Ghrelin inhibits doxorubicin cardiotoxicity by inhibiting excessive autophagy through AMPK and p38-MAPK.** *Biochem Pharmacol.* 2014; **88**(3): 334–50.  
[PubMed Abstract](#) | [Publisher Full Text](#)
82. Zhu H, Luo P, Fu Y, *et al.*: **Dihydropyridinone prevents cardiotoxicity and enhances anticancer activity induced by adriamycin.** *Oncotarget.* 2015; **6**(5): 3254–6.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
83. Granados-Principal S, El-Azem N, Pamplona R, *et al.*: **Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer.** *Biochem Pharmacol.* 2014; **90**(1): 25–33.  
[PubMed Abstract](#) | [Publisher Full Text](#)
84. Saleem MT, Chetty MC, Kavimani S: **Antioxidants and tumor necrosis factor alpha-inhibiting activity of sesame oil against doxorubicin-induced cardiotoxicity.** *Ther Adv Cardiovasc Dis.* 2014; **8**(1): 4–11.  
[PubMed Abstract](#) | [Publisher Full Text](#)
85. Su S, Li Q, Liu Y, *et al.*: **Sesamin ameliorates doxorubicin-induced cardiotoxicity: involvement of Sirt1 and Mn-SOD pathway.** *Toxicol Lett.* 2014; **224**(2): 257–63.  
[PubMed Abstract](#) | [Publisher Full Text](#)
86. Wang XL, Wang X, Xiong LL, *et al.*: **Salidroside improves doxorubicin-induced cardiac dysfunction by suppression of excessive oxidative stress and cardiomyocyte apoptosis.** *J Cardiovasc Pharmacol.* 2013; **62**(6): 512–23.  
[PubMed Abstract](#) | [Publisher Full Text](#)
87. Mohamed HE, El-Sweify SE, Hagar HH: **The protective effect of glutathione administration on adriamycin-induced acute cardiac toxicity in rats.** *Pharmacol Res.* 2000; **42**(2): 115–21.  
[PubMed Abstract](#) | [Publisher Full Text](#)
88. Sun J, Sun G, Meng X, *et al.*: **Isorhamnetin protects against doxorubicin-induced cardiotoxicity *in vivo* and *in vitro*.** *PLoS One.* 2013; **8**(5): e64526.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

89. Fouad AA, Albuali WH, Al-Mulhim AS, *et al.*: **Cardioprotective effect of cannabidiol in rats exposed to doxorubicin toxicity.** *Environ Toxicol Pharmacol.* 2013; **36**(2): 347–5.  
[PubMed Abstract](#) | [Publisher Full Text](#)
90. Dolinsky VW, Rogan KJ, Sung MM, *et al.*: **Both aerobic exercise and resveratrol supplementation attenuate doxorubicin-induced cardiac injury in mice.** *Am J Physiol Endocrinol Metab.* 2013; **305**(2): E243–53.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
91. **F** Hajra S, Patra AR, Basu A, *et al.*: **Prevention of doxorubicin (DOX)-induced genotoxicity and cardiotoxicity: Effect of plant derived small molecule indole-3-carbinol (I3C) on oxidative stress and inflammation.** *Biomed Pharmacother.* 2018; **101**: 228–43.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
92. Yu X, Cui L, Zhang Z, *et al.*:  **$\alpha$ -Linolenic acid attenuates doxorubicin-induced cardiotoxicity in rats through suppression of oxidative stress and apoptosis.** *Acta Biochim Biophys Sin (Shanghai).* 2013; **45**(10): 817–26.  
[PubMed Abstract](#) | [Publisher Full Text](#)
93. Al-Abd AM, Al-Abbasi FA, Asaad GF, *et al.*: **Dioxo potentiates the cytotoxic profile of doxorubicin and protects from its cardiotoxicity.** *Eur J Pharmacol.* 2013; **718**(1–3): 361–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
94. Gharanei M, Hussain A, Jannah O, *et al.*: **Attenuation of doxorubicin-induced cardiotoxicity by mdm1-1: a mitochondrial division/mitophagy inhibitor.** *PLoS One.* 2013; **8**(10): e77713.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
95. Tebbi CK, London WB, Friedman D, *et al.*: **Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.** *J Clin Oncol.* 2007; **25**(5): 493–500.  
[PubMed Abstract](#) | [Publisher Full Text](#)
96. van Dalen EC, Caron HN, Dickinson HO, *et al.*: **Cardioprotective interventions for cancer patients receiving anthracyclines.** *Cochrane Database Syst Rev.* 2011; **6**: CD003917.  
[PubMed Abstract](#) | [Publisher Full Text](#)
97. Barry EV, Vrooman LM, Dahlberg SE, *et al.*: **Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane.** *J Clin Oncol.* 2008; **26**(7): 1106–11.  
[PubMed Abstract](#) | [Publisher Full Text](#)
98. Seif AE, Walker DM, Li Y, *et al.*: **Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients.** *Pediatr Blood Cancer.* 2015; **62**(4): 704–9.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
99. **F** Asselin BL, Devidas M, Chen L, *et al.*: **Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404.** *J Clin Oncol.* 2016; **34**(8): 854–62.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
100. Oliveira PJ, Bjork JA, Santos MS, *et al.*: **Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity.** *Toxicol Appl Pharmacol.* 2004; **200**(2): 159–68.  
[PubMed Abstract](#) | [Publisher Full Text](#)
101. Kalay N, Basar E, Ozdogru I, *et al.*: **Protective effects of carvedilol against anthracycline-induced cardiomyopathy.** *J Am Coll Cardiol.* 2006; **48**(11): 2258–62.  
[PubMed Abstract](#) | [Publisher Full Text](#)
102. **F** Nabati M, Janbabai G, Baghyari S, *et al.*: **Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-Induced Cardiotoxicity.** *J Cardiovasc Pharmacol.* 2017; **69**(5): 279–85.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
103. Cardinale D, Ciceri F, Latini R, *et al.*: **Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial.** *Eur J Cancer.* 2018; **94**: 126–37.  
[PubMed Abstract](#) | [Publisher Full Text](#)
104. **F** Boekhout AH, Gietema JA, Milojkovic Kerklaan B, *et al.*: **Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.** *JAMA Oncol.* 2016; **2**(8): 1030–7.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
105. Tallaj JA, Franco V, Rayburn BK, *et al.*: **Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure.** *J Heart Lung Transplant.* 2005; **24**(12): 2196–201.  
[PubMed Abstract](#) | [Publisher Full Text](#)
106. Bosch X, Rovira M, Sitges M, *et al.*: **Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiON of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies).** *J Am Coll Cardiol.* 2013; **61**(23): 2355–62.  
[PubMed Abstract](#) | [Publisher Full Text](#)
107. Payne DL, Nohria A: **Prevention of Chemotherapy Induced Cardiomyopathy.** *Curr Heart Fail Rep.* 2017; **14**(5): 398–403.  
[PubMed Abstract](#) | [Publisher Full Text](#)
108. Guglin M, Munster P, Fink A, *et al.*: **Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: A rationale and design of a randomized clinical trial.** *Am Heart J.* 2017; **188**: 87–92.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
109. Seicean S, Seicean A, Plana JC, *et al.*: **Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: An observational clinical cohort study.** *J Am Coll Cardiol.* 2012; **60**(23): 2384–90.  
[PubMed Abstract](#) | [Publisher Full Text](#)
110. Chotenimitkhun R, D'Agostino R Jr, Lawrence JA, *et al.*: **Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function.** *Can J Cardiol.* 2015; **31**(3): 302–7.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
111. Gabizon AA, Lyass O, Berry GJ, *et al.*: **Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies.** *Cancer Invest.* 2004; **22**(5): 663–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
112. **F** Skubitz KM, Blaes AH, Konety SH, *et al.*: **Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.** *Cancer Chemother Pharmacol.* 2017; **80**(4): 787–98.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
113. Smith LA, Cornelius VR, Plummer CJ, *et al.*: **Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials.** *BMC Cancer.* 2010; **10**: 337.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
114. Jones LW, Habel LA, Weltzien E, *et al.*: **Exercise and Risk of Cardiovascular Events in Women With Nonmetastatic Breast Cancer.** *J Clin Oncol.* 2016; **34**(23): 2743–9.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
115. Haykowsky MJ, Mackey JR, Thompson RB, *et al.*: **Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training.** *Clin Cancer Res.* 2009; **15**(15): 4963–7.  
[PubMed Abstract](#) | [Publisher Full Text](#)
116. Cardinale D, Sandri MT, Martinoni A, *et al.*: **Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy.** *J Am Coll Cardiol.* 2000; **36**(2): 517–22.  
[PubMed Abstract](#) | [Publisher Full Text](#)
117. Cardinale D, Colombo A, Torrisi R, *et al.*: **Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.** *J Clin Oncol.* 2010; **28**(25): 3910–6.  
[PubMed Abstract](#) | [Publisher Full Text](#)
118. Kilickap S, Barista I, Akgul E, *et al.*: **cTnT can be a useful marker for early detection of anthracycline cardiotoxicity.** *Ann Oncol.* 2005; **16**(5): 798–804.  
[PubMed Abstract](#) | [Publisher Full Text](#)
119. **F** De Iulius F, Salerno G, Taglieri L, *et al.*: **Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients.** *Tumour Biol.* 2016; **37**(3): 3379–87.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
120. Nousiainen T, Vanninen E, Jantunen E, *et al.*: **Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction.** *J Intern Med.* 2002; **251**(3): 228–34.  
[PubMed Abstract](#) | [Publisher Full Text](#)
121. Sawaya H, Sebag IA, Plana JC, *et al.*: **Early detection and prediction of cardiotoxicity in chemotherapy-treated patients.** *Am J Cardiol.* 2011; **107**(9): 1375–80.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
122. Katsurada K, Ichida M, Sakuragi M, *et al.*: **High-sensitivity troponin T as a marker to predict cardiotoxicity in breast cancer patients with adjuvant trastuzumab therapy.** *Springerplus.* 2014; **3**: 620.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
123. Ky B, Putt M, Sawaya H, *et al.*: **Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab.** *J Am Coll Cardiol.* 2014; **63**(8): 809–16.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
124. Ylänen K, Poutanen T, Savukoski T, *et al.*: **Cardiac biomarkers indicate a need for sensitive cardiac imaging among long-term childhood cancer survivors exposed to anthracyclines.** *Acta Paediatr.* 2015; **104**(3): 313–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
125. Garrone O, Crosetto N, Lo Nigro C, *et al.*: **Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis.** *Cardiovasc Toxicol.* 2012; **12**(2): 135–42.  
[PubMed Abstract](#) | [Publisher Full Text](#)
126. Onitilo AA, Engel JM, Stankowski RV, *et al.*: **High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.** *Breast Cancer Res Treat.* 2012; **134**(1): 291–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
127. Putt M, Hahn VS, Januzzi JL, *et al.*: **Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab.** *Clin Chem.* 2015; **61**(9): 1164–72.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

128. Arslan D, Cihan T, Kose D, *et al.*: **Growth-differentiation factor-15 and tissue doppler imaging in detection of asymptomatic anthracycline cardiomyopathy in childhood cancer survivors.** *Clin Biochem.* 2013; 46(13–14): 1239–43. [PubMed Abstract](#) | [Publisher Full Text](#)
129. Finkelman BS, Putt M, Wang T, *et al.*: **Arginine-Nitric Oxide Metabolites and Cardiac Dysfunction in Patients With Breast Cancer.** *J Am Coll Cardiol.* 2017; 70(2): 152–62. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
130. Horacek JM, Vasatova M, Tichy M, *et al.*: **The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia.** *Exp Oncol.* 2010; 32(2): 97–9. [PubMed Abstract](#)
131. Mercurio G, Cadeddu C, Piras A, *et al.*: **Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers.** *Oncologist.* 2007; 12(9): 1124–33. [PubMed Abstract](#) | [Publisher Full Text](#)
132. Ma Y, Kang W, Bao Y, *et al.*: **Clinical significance of ischemia-modified albumin in the diagnosis of doxorubicin-induced myocardial injury in breast cancer patients.** *PLoS One.* 2013; 8(11): e79426. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
133. Aminkeung F, Bhavsar AP, Visscher H, *et al.*: **A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.** *Nat Genet.* 2015; 47(9): 1079–84. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
134. **F** Wang X, Sun CL, Quiñones-Lombrana A, *et al.*: **CEL4 Variant and Anthracycline-Related Cardiomyopathy: A Children's Oncology Group Genome-Wide Association Study.** *J Clin Oncol.* 2016; 34(8): 863–70. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
135. **F** Schneider BP, Shen F, Gardner L, *et al.*: **Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure.** *Clin Cancer Res.* 2017; 23(1): 43–51. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
136. Hahm S, Dresner HS, Podwall D, *et al.*: **DNA biomarkers antecede semiquantitative anthracycline cardiomyopathy.** *Cancer Invest.* 2003; 21(1): 53–67. [PubMed Abstract](#) | [Publisher Full Text](#)
137. Mori Y, Kondo C, Tomomura Y, *et al.*: **Identification of potential genomic biomarkers for early detection of chemically induced cardiotoxicity in rats.** *Toxicology.* 2010; 271(1–2): 36–44. [PubMed Abstract](#) | [Publisher Full Text](#)
138. Desai VG, C Kwekel J, Vijay V, *et al.*: **Early biomarkers of doxorubicin-induced heart injury in a mouse model.** *Toxicol Appl Pharmacol.* 2014; 281(2): 221–9. [PubMed Abstract](#) | [Publisher Full Text](#)
139. Vacchi-Suzzi C, Bauer Y, Berridge BR, *et al.*: **Perturbation of microRNAs in rat heart during chronic doxorubicin treatment.** *PLoS One.* 2012; 7(7): e40395. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
140. Horie T, Ono K, Nishi H, *et al.*: **Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway.** *Cardiovasc Res.* 2010; 87(4): 656–64. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
141. Eryilmaz U, Demirci B, Aksun S, *et al.*: **S100A1 as a Potential Diagnostic Biomarker for Assessing Cardiotoxicity and Implications for the Chemotherapy of Certain Cancers.** *PLoS One.* 2015; 10(12): e0145418. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
142. ElZarrad MK, Mukhopadhyay P, Mohan N, *et al.*: **Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice.** *PLoS One.* 2013; 8(11): e79543. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
143. Bao GY, Wang HZ, Shang YJ, *et al.*: **Quantitative proteomic study identified cathepsin B associated with doxorubicin-induced damage in H9c2 cardiomyocytes.** *Biosci Trends.* 2012; 6(6): 283–7. [PubMed Abstract](#) | [Publisher Full Text](#)
144. Petricoin EF, Rajapaske V, Herman EH, *et al.*: **Toxicoproteomics: serum proteomic pattern diagnostics for early detection of drug induced cardiac toxicities and cardioprotection.** *Toxicol Pathol.* 2004; 32 Suppl 1: 122–30. [PubMed Abstract](#) | [Publisher Full Text](#)
145. Li Y, Ju L, Hou Z, *et al.*: **Screening, verification, and optimization of biomarkers for early prediction of cardiotoxicity based on metabolomics.** *J Proteome Res.* 2015; 14(6): 2437–45. [PubMed Abstract](#) | [Publisher Full Text](#)
146. Todorova VK, Beggs ML, Delongchamp RR, *et al.*: **Transcriptome profiling of peripheral blood cells identifies potential biomarkers for doxorubicin cardiotoxicity in a rat model.** *PLoS One.* 2012; 7(11): e48398. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
147. **F** Lenihan DJ, Stevens PL, Massey M, *et al.*: **The Utility of Point-of-Care Biomarkers to Detect Cardiotoxicity During Anthracycline Chemotherapy: A Feasibility Study.** *J Card Fail.* 2016; 22(6): 433–8. [PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
148. Kim YH, Kirsop J, Tang WH: **Alternative Biomarkers for Combined Biology.** *Heart Fail Clin.* 2017; 13(2): 381–401. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
149. Oliveira-Carvalho V, Ferreira LR, Bocchi EA: **Circulating mir-208a fails as a biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients.** *J Appl Toxicol.* 2015; 35(9): 1071–2. [PubMed Abstract](#) | [Publisher Full Text](#)
150. Steinberg JS, Cohen AJ, Wasserman AG, *et al.*: **Acute arrhythmogenicity of doxorubicin administration.** *Cancer.* 1987; 60(6): 1213–8. [PubMed Abstract](#) | [Publisher Full Text](#)
151. Schwartz RG, McKenzie WB, Alexander J, *et al.*: **Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiography.** *Am J Med.* 1987; 82(6): 1109–18. [PubMed Abstract](#) | [Publisher Full Text](#)
152. McKillop JH, Bristow MR, Goris ML, *et al.*: **Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity.** *Am Heart J.* 1983; 106(5 Pt 1): 1048–56. [PubMed Abstract](#) | [Publisher Full Text](#)
153. Gottdiener JS, Mathisen DJ, Borer JS, *et al.*: **Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography.** *Ann Intern Med.* 1981; 94(4 pt 1): 430–5. [PubMed Abstract](#)
154. Thavendiranathan P, Grant AD, Negishi T, *et al.*: **Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy.** *J Am Coll Cardiol.* 2013; 61(1): 77–84. [PubMed Abstract](#) | [Publisher Full Text](#)
155. Khouri MG, Hornsby WE, Risum N, *et al.*: **Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy.** *Breast Cancer Res Treat.* 2014; 143(3): 531–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
156. Walker J, Bhullar N, Fallah-Rad N, *et al.*: **Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging.** *J Clin Oncol.* 2010; 28(21): 3429–36. [PubMed Abstract](#) | [Publisher Full Text](#)
157. Negishi K, Negishi T, Haluska BA, *et al.*: **Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection.** *Eur Heart J Cardiovasc Imaging.* 2014; 15(3): 324–31. [PubMed Abstract](#) | [Publisher Full Text](#)
158. Armstrong GT, Plana JC, Zhang N, *et al.*: **Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging.** *J Clin Oncol.* 2012; 30(23): 2876–84. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
159. Drafts BC, Twomey KM, D'Agostino R Jr, *et al.*: **Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.** *JACC Cardiovasc Imaging.* 2013; 6(8): 877–85. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
160. Lightfoot JC, D'Agostino RB Jr, Hamilton CA, *et al.*: **Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model.** *Circ Cardiovasc Imaging.* 2010; 3(5): 550–8. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
161. Jordan JH, D'Agostino RB Jr, Hamilton CA, *et al.*: **Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance.** *Circ Cardiovasc Imaging.* 2014; 7(6): 872–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
162. Jones LW, Courneya KS, Mackey JR, *et al.*: **Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum.** *J Clin Oncol.* 2012; 30(20): 2530–7. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
163. Su H, Gorodny N, Gomez LF, *et al.*: **Noninvasive molecular imaging of apoptosis in a mouse model of anthracycline-induced cardiotoxicity.** *Circ Cardiovasc Imaging.* 2015; 8(2): e001952. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

# Open Peer Review

Current Referee Status:



---

## Editorial Note on the Review Process

F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version).

---

## The referees who approved this article are:

### Version 1

- 1 **Ana Barac** Medstar Washington Hospital Center, Medstar Heart and Vascular Institute, Washington, USA  
**Competing Interests:** No competing interests were disclosed.
- 2 **Edimar A Bocchi Monica S Ávila** Heart Failure Department, Heart Institute (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil  
**Competing Interests:** No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact [research@f1000.com](mailto:research@f1000.com)

F1000Research